18 Apr Russell Barkley Responds to NYT ADHD Article
RUSSELL BARKLEY’S ADHD RESPONSE TO PAUL TOUGH’S 2025 FEATURE

New York Times Magazine ADHD Article Corrections: Understanding the Controversy
In a detailed four-part video series, clinical psychologist and ADHD expert Dr. Russell Barkley critiques Paul Tough’s April 2025 New York Times Magazine article, arguing that it misrepresents the behavioral sciences, misleads readers about ADHD medication effectiveness, and fuels ADHD myths that can harm public trust in psychiatry.
Barkley’s response highlights the importance of distinguishing mental health science from media narratives that may distort findings. His analysis brings attention to corrections needed in ADHD reporting, particularly regarding stimulant medications and their role in managing symptoms for patients across the lifespan.
Economist Articles Connection
Barkley points out that the NYT article echoes themes found in two recent Economist pieces:
He sees this trend as part of a broader media narrative that downplays the seriousness of ADHD as a legitimate neurodevelopmental condition.
Part 1: Challenging the Foundation of the NYT Article
In Part 1 of his video series, Barkley critiques the article’s early sections, which reference:
- Dr. James Swanson’s evolving views on ADHD
- The landmark Multimodal Treatment Study of ADHD (MTA)
- ADHD prevalence rates reported by the Centers for Disease Control and Prevention (CDC)
Part 2: The Same Old Myths Rehashed
Barkley opens Part 2 by correcting a minor misstatement from Part 1 regarding the CDC survey question. Though he acknowledges the mistake, he maintains his point that such data likely overstates actual ADHD prevalence.
He then tackles recurring myths in the NYT article — some recycled from anti-psychiatry groups like the Church of Scientology. Key debunked claims include:
- Rising prescriptions reflect better recognition, not overuse.
- ADHD meds aren’t based on flawed brain repair theories — they’re used because they work.
- Environmental factors aren’t a new discovery — they’ve been part of ADHD research for 50+ years.
- DSM isn’t a rigid medical straightjacket — it’s a guide based on evidence, and the use of “often” in symptom criteria adds clinical flexibility.
- Dimensional traits don’t disprove ADHD — many disorders exist on a spectrum and are still medically recognized.
Barkley calls this a case of “journalism by omission,” where context is deliberately left out, misleading readers and undermining scientific consensus.
ADHD Newsletter Summary: What You Need to Know
Headline Points:
- ADHD (attention deficit hyperactivity disorder) is a neurodevelopmental disorder, not a personality trait or behavior.
- Stimulant medications like Ritalin and Adderall have a positive effect when used appropriately.
- ADHD affects academic achievement, behavior, and cognitive ability, especially in children and adolescents.
- Doctors and clinicians emphasize early intervention and sustained support as essential.
- Clinical psychologists, psychiatrists, and professors of psychiatry agree: ADHD should be taken seriously and treated accordingly.

Part 3: Selective Science and Ignored Evidence
In Part 3, Barkley continues his breakdown by addressing more scientific inaccuracies:
- “Arbitrary” Diagnosis Cut-offs: Barkley says clinical thresholds may be arbitrary, but they’re essential for determining who needs support.
- Biomarkers Debate: ADHD lacks a definitive biomarker — but so do all mental disorders. Barkley notes substantial genetic and neuroimaging evidence still supports ADHD’s neurobiological basis.
- Missing the 2021 Consensus Statement: The NYT article mentions the 2002 consensus while ignoring the more recent, robust 2021 statement that outlines over 200 evidence-based conclusions.
- Neurological Evidence Ignored: Barkley cites hundreds of neuroimaging studies showing brain structure and connectivity differences in ADHD patients.
- Treatment Advancements Dismissed: Barkley calls out the article’s claim that treatments haven’t changed in 90 years — listing new medications, delivery systems, behavioral interventions, and coaching strategies.
- Academic Achievement Argument: The article argues meds don’t improve grades. Barkley counters that ADHD is a disorder of performance, not intelligence — meds help people demonstrate what they already know.
- Positive Outcomes Ignored: Barkley lists benefits in driving safety, employment, college success, behavior, and reduced injuries — none of which are mentioned in the article.
Part 4: A Misleading Narrative
In his final video, Barkley takes aim at what he sees as the most harmful misrepresentations:
- Long-term medication effects: Claims that benefits “fade” over time misread the MTA study design.
- Height suppression: Acknowledged, but Barkley says it’s minimal and outweighed by treatment benefits.
- Psychosis risk: Misleading — the study cited was retrospective, not based on general ADHD patients.
- The idea that meds offer no long-term benefits: Barkley says this is a mischaracterization of how chronic disorders are managed.
- Symptom fluctuation: Even if symptoms change, most individuals still meet criteria over time.
- Category vs. dimension: Barkley calls this critique trivial — clinicians already rate severity within categories.
- Involving kids in med decisions: Barkley opposes letting children decide on treatment for long-term health risks.
- Environment-only treatment: While environmental supports matter, Barkley says eliminating meds isn’t realistic.
Behavioral Science Breakdown: The MTA Study in Context
The Multimodal Treatment Study of ADHD (MTA), a key reference in the article, is used to support claims that stimulant tolerance limits long-term benefits.
Barkley counters that:
- The study’s treatment groups became mixed after 14 months, invalidating later-stage comparisons.
- In the controlled phase, stimulant medications and combined interventions outperformed other approaches.
Child ADHD Rates: Are CDC Statistics Inflated?
He cites meta-analyses and NIMH data showing more conservative and rigorously established prevalence estimates. Tough’s article cites CDC statistics stating:
- Over 7 million American adolescents and children have ADHD.
- 23% of high school students, especially 17-year-old boys, have received a diagnosis.
Barkley disputes this, noting:
- Many of these are based on parent-reported symptoms, not clinical assessments.
- Peer-reviewed studies suggest a more accurate prevalence of 5–7% in children and 3–5% in adults.
- He stresses the importance of accurate, time-sensitive diagnoses — emphasizing that early time diagnoses can improve treatment success and prevent complications later in life.

Does ADHD Medications Work? Examining the Effects
Barkley reinforces that stimulant medications like Adderall and Ritalin:
- Improve attention, impulse control, and executive function
- Support academic and behavioral outcomes
- Carry side effects, but those are manageable with medical oversight
- Should be used in tandem with therapy and accommodations when possible
According to this article, which centers on the long-term effectiveness of Ritalin, highlighting the MTA study, which initially showed short-term improvement in attention among children with ADHD. However, by 36 months, the benefits diminished, and children on the drug showed similar symptoms to those who never took it. The article also questions the rigidity of ADHD as a diagnosis, noting that symptoms fluctuate over time, there’s no clear biological marker, and many children without initial diagnoses later met the criteria — suggesting a more nuanced, context-dependent understanding of attention issues.
Other Interventions: Beyond Stimulant Medications
Barkley supports a multimodal treatment plan:
- Medications
- Behavioral therapy
- Environmental accommodations
- Educational interventions
He also highlights the value of early behavioral support — in homes, schools, and preschools — as a prevention strategy to reduce severity later in life.
ADHD and Behavior in Public Discourse
Barkley critiques growing narratives suggesting ADHD is:
- Merely a personality style
- A temporary childhood phase
- Better handled by changing society than by treating individuals
He believes these framings confuse caregivers and minimize the struggles of those with genuine ADHD. He urges readers to turn to clinical resources and consensus statements — not opinion pieces — for evidence-based guidance.
Final Thoughts
Dr. Russell Barkley’s four-part response to the New York Times Magazine article isn’t just about correcting facts — it’s about defending the integrity of mental health science. He argues that ADHD is too often misunderstood in public discourse, with media pieces like this one reviving old myths, misusing research, and downplaying decades of evidence.
His critique reminds us of a simple truth: ADHD is a well-documented, neurodevelopmental disorder that requires informed, individualized care — not ideological debate. Oversimplifying the science or ignoring context does more than confuse the public — it risks undermining treatment, delaying diagnosis, and stigmatizing the people who live with ADHD every day.
If the conversation around ADHD is going to evolve, it has to start with evidence — not headlines.

Craig Selinger
Latest posts by Craig Selinger (see all)
- Making Sense Of Sensory Triggers And Helpful Tools - February 3, 2026
- How Music Can Help Ease Anxiety In Children - February 3, 2026
- Hyperfocus and ADHD: Strength or Struggle? - January 27, 2026












No Comments